Specific classification and new therapeutic targets for neuroendocrine prostate cancer: A patient-based, diagnostic study.
Specific classification and new therapeutic targets for neuroendocrine prostate cancer: A patient-based, diagnostic study.
复制标题
神经内分泌前列腺癌的具体分类和新的治疗靶点：基于患者的诊断研究
DOI：
10.3389/fgene.2022.955133
复制
发表时间：
2022
影响因子：
3.7
通讯作者：
Jiang, Ning
中科院分区：
文献类型：
--
作者：
Wang, YouZhi;Wu, Ning;Wang, KeKe;Liao, YiHao;Guo, JiaNing;Zhong, BoQiang;Guo, Tao;Liang, JiaMing;Jiang, Ning
关键词：
目的：神经内分泌前列腺癌（NEPC）是前列腺癌（PC）的一种侵袭性变体，可能新发或在既往接受过前列腺腺癌激素治疗的患者中作为耐药机制出现。在我们的研究中，神经内分泌分化前列腺癌（NEDPC）和NEPC之间似乎有很强的相关性。本研究的目的包括探索NEDPC是否是高危前列腺癌（HRPC）进展为NEPC的中间阶段，并确定与NEPC治疗中生存相关的风险因素和新靶点。方法：选择进展为高危前列腺癌并以神经内分泌为特征的患者。我们收集了三种癌症患者的临床资料和特点：转移的发生率、转移的部位和时间、复发率、相关治疗方法等，通过实验和数据库比较三组的异同。结果如下：通过对临床资料和免疫组化结果的分析，我们发现，在从PC进展到NEPC的过程中，似乎有一个神经内分泌分化（NED）状态的临床特征。因此，通过将NEDPC视为NEPC之前的PC进展阶段，寻找新的治疗靶点将是有益的。无转移生存曲线和免疫组化结果提示，NEDPC可作为诊断NEPC的一个前期状态。结论：NEPC是一种常被忽视的晚期PC症状，预后不良。因此，将NEDPC视为NEPC之前PC进展的阶段，寻找新的治疗靶点将是有益的。
Objective: Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer (PC) that may arise de novo or in patients previously treated with hormonal therapies for prostate adenocarcinoma as a mechanism of resistance. In our investigation, there appeared to be a strong correlation between neuroendocrine differentiation prostate cancer (NEDPC) and NEPC. The objectives of this study included exploring whether NEDPC is an intermediate stage in the progression of high-risk prostate cancer (HRPC) to NEPC and identifying risk factors and new targets associated with survival in the treatment of NEPC. Methods: The selected prostate cancer patients were progressed to high-risk and characterized by neuroendocrine. We collected the clinical data and characteristics of patients with three types of cancer: the incidence of metastasis, site and time of metastasis, recurrence rate, related treatment methods, etc. The similarity and differences of the three groups were compared through experiment and database. Results: By analyzing the clinical data and immunohistochemical results, we found that there seems to be a clinical feature of neuroendocrine differentiation (NED) status in between when patients progress from PC to NEPC. Finding novel treatment targets would therefore be beneficial by taking into account NEDPC as the stage of PC progression prior to NEPC. The metastasis-free survival curve and the immunohistochemical results are informing us that NEDPC can be a pre-state for diagnosing NEPC. Conclusion: NEPC is a late PC symptom that is frequently disregarded and has a bad prognosis. Finding novel treatment targets would therefore be beneficial by taking into account NEDPC as the stage of PC progression prior to NEPC.
登录
查看更多内容
影响因子：
23.4
作者：
Nabid, Abdenour;Carrier, Nathalie;Souhami, Luis
通讯作者：
Souhami, Luis
雄激素无关前列腺癌治疗的临床考虑。
影响因子：
4.8
作者：
Berchuck JE;Viscuse PV;Beltran H;Aparicio A
通讯作者：
Aparicio A
影响因子：
45.3
作者：
Papandreou, CN;Daliani, DD;Logothetis, CJ
通讯作者：
Logothetis, CJ
DOI：
10.1158/1078-0432.ccr-13-3309
发表时间：
2014-06-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Beltran H;Tomlins S;Aparicio A;Arora V;Rickman D;Ayala G;Huang J;True L;Gleave ME;Soule H;Logothetis C;Rubin MA
通讯作者：
Rubin MA
影响因子：
45.3
作者：
Tagawa, Scott T.
通讯作者：
Tagawa, Scott T.